Clinical Trials Logo

Clinical Trial Summary

This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks. Assessment of safety and tolerability of drug combination


Clinical Trial Description

This is an open-label, phase 1b trial of ADI-PEG 20 in combination with pembrolizumab in subjects with advanced cancers. Dose escalation will occur using a 3 + 3 + 3 design. The first subject in a dose escalation cohort must have had treatment with ADI-PEG 20 + pembrolizumab with a week of follow up) before the next 2 subjects are enrolled. Thus subjects 2 and 3 may be enrolled on day 8 if there is no dose limiting toxicity (DLT) in subject 1. No additional delay is required between treating subjects 4 to 6 or 7 to 9 in an expanded cohort. Before proceeding to the next cohort dose level, the first 3 eligible subjects in each cohort will have received at least 21 days of treatment (i.e. at least 2 of the expected 3 doses of ADI-PEG 20 + one dose of pembrolizumab). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03254732
Study type Interventional
Source Polaris Group
Contact
Status Terminated
Phase Phase 1
Start date July 14, 2017
Completion date February 25, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02792465 - A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors Phase 1
Terminated NCT00886782 - A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03956680 - An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers Phase 1
Completed NCT03512340 - Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers Phase 1
Terminated NCT00337376 - A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers Phase 1
Completed NCT00478101 - Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain Phase 2
Completed NCT01019941 - Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer Phase 1
Completed NCT02694822 - AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy Phase 1/Phase 2